Shire launches Fosrenol in Japan

16 March 2009

UK specialty biopharmaceutical company Shire has announced the Japanese launch of Fosrenol (lanthanum carbonate), through its strategic alliance  partner Bayer Yakuhin.

Fosrenol is claimed to be the first, commercially-available  non-calcium, non-resin phosphate binder in Japan and is used in the  control of hyperphosphatemia in chronic renal failure patients on  dialysis. Bayer Yakuhin received an exclusive license from Shire in  December 2003 to develop the drug  completing Phase II and Phase III  clinical trials in the Japanese population.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight